Phospho-ITK (Tyr512) Antibody - #AF8072

Fig. 1. ITK is overexpressed in NKTCL and elevated ITK expression is associated with poor survival. A ITK gene expression (mean ± SD) of normal NK cells (n = 13), NKTCL patient samples (n = 58) and NKTCL cell lines (n = 14) from GEO database. One-way ANOVA and Dunnett post hoc multiple comparisons were used. B, C Validation of ITK mRNA and protein expression in normal NK and NKTCL cell lines (NK-YS, KHYG-1, YT and YTS) using real-time PCR (normalized to GAPDH as internal control, mean ± SD) and immunoblotting analysis (GAPDH used as loading control). D The p-ITK(Tyr512) expression of NKTCL patient samples (n = 8), Scale bar = 100 μm, up panel was representative pictures of IHC and bottom panel was colored images from QuPath. Patients marked in red died at cutoff day. E Sankey diagram demonstrated the correlation between p-ITK(Tyr512) H-score (calculated by QuPath) of patient samples and clinical information. Patients with higher p-ITK(Tyr512) expression seemed to be resistant to ASP and to have shorter survival. F Kaplan–Meier curve for the OS of NKTCL patients (n = 32) in GSE90784 according to ITK mRNA expression (ITK low vs ITK high). The p value was calculated via Log-rank test. G Univariate analysis identified risk factors of available NKTCL patients in GSE90784 set (n = 25) and forward stepwise Cox regression was used. ITK mRNA expression was one of the independent adverse risk factors for OS in NKTCL. HR, hazard ratio. CI, confidence interval. OS, overall survival. For all data, ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns (not statistically significant), p ≥ 0.05.

Fig. 1. ITK is overexpressed in NKTCL and elevated ITK expression is associated with poor survival. A ITK gene expression (mean ± SD) of normal NK cells (n = 13), NKTCL patient samples (n = 58) and NKTCL cell lines (n = 14) from GEO database. One-way ANOVA and Dunnett post hoc multiple comparisons were used. B, C Validation of ITK mRNA and protein expression in normal NK and NKTCL cell lines (NK-YS, KHYG-1, YT and YTS) using real-time PCR (normalized to GAPDH as internal control, mean ± SD) and immunoblotting analysis (GAPDH used as loading control). D The p-ITK(Tyr512) expression of NKTCL patient samples (n = 8), Scale bar = 100 μm, up panel was representative pictures of IHC and bottom panel was colored images from QuPath. Patients marked in red died at cutoff day. E Sankey diagram demonstrated the correlation between p-ITK(Tyr512) H-score (calculated by QuPath) of patient samples and clinical information. Patients with higher p-ITK(Tyr512) expression seemed to be resistant to ASP and to have shorter survival. F Kaplan–Meier curve for the OS of NKTCL patients (n = 32) in GSE90784 according to ITK mRNA expression (ITK low vs ITK high). The p value was calculated via Log-rank test. G Univariate analysis identified risk factors of available NKTCL patients in GSE90784 set (n = 25) and forward stepwise Cox regression was used. ITK mRNA expression was one of the independent adverse risk factors for OS in NKTCL. HR, hazard ratio. CI, confidence interval. OS, overall survival. For all data, ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; ns (not statistically significant), p ≥ 0.05.